What’s Keytruda’s patent expiration date?
I can’t determine a specific “Keytruda patent expiration date” from the information available here. Keytruda (pembrolizumab) is typically covered by multiple patents across different countries and claims (for example, composition, formulations, and methods of use), so there isn’t one single expiration date that applies universally.
Which date matters for biosimilar entry?
Even when patents expire, biosimilar or other competition timing can still be affected by:
- country-by-country patent coverage (different expiration dates),
- patent litigation status,
- regulatory exclusivities (which are separate from patent terms),
- additional “secondary” patents on uses or manufacturing.
Because of that, the relevant date depends on the jurisdiction (U.S., EU, UK, etc.) and what kind of competition you mean (biosimilar entry vs. generic-like substitution).
If you want an exact date, what details should you provide?
To give a precise expiration date, I need at least:
- the country/jurisdiction (e.g., U.S. or EU),
- whether you mean a specific patent number (if you have one),
- whether you care about biosimilar launch timing or just the end of the main underlying patent term.
Sources: none provided.